scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00392-007-0540-X |
P698 | PubMed publication ID | 17593313 |
P50 | author | Wolfgang Koenig | Q20172819 |
P2093 | author name string | R Müller | |
C Müller | |||
M Möckel | |||
R Dietz | |||
T Störk | |||
R Gareis | |||
O Danne | |||
J O Vollert | |||
P2860 | cites work | Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar | Q46990506 |
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay me | Q47829708 | ||
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. | Q48329269 | ||
Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. | Q48591877 | ||
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide | Q48630098 | ||
Models for diagnosing chest pain: is CART helpful? | Q52267061 | ||
Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis | Q57192508 | ||
Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions | Q59704158 | ||
Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase | Q69614163 | ||
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group | Q73088406 | ||
Predictive factors of restenosis after coronary stent placement | Q73857145 | ||
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease | Q73901926 | ||
Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology | Q74205749 | ||
Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma | Q78056182 | ||
Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room | Q78448050 | ||
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation | Q78722335 | ||
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy | Q80356150 | ||
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI | Q22252998 | ||
Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome | Q28240315 | ||
Platelet-activating factor acetylhydrolases | Q28243333 | ||
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review | Q30826404 | ||
Present treatment of acute myocardial infarction in patients over 75 years--data from the Berlin Myocardial Infarction Registry (BHIR). | Q31043179 | ||
Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima | Q33890396 | ||
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction | Q33917874 | ||
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g | Q34154695 | ||
Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target | Q34443175 | ||
Lp-PLA2: an emerging biomarker of coronary heart disease | Q34606938 | ||
Platelet-activating factor acetylhydrolase (PAF-AH). | Q34619701 | ||
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase | Q35062409 | ||
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease | Q35178997 | ||
A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure | Q35914841 | ||
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease | Q38410603 | ||
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G | Q40479587 | ||
Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase | Q41887100 | ||
Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy | Q43604021 | ||
Human macrophages secret platelet-activating factor acetylhydrolase | Q43778334 | ||
N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes | Q44446907 | ||
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study | Q44752425 | ||
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up | Q45200533 | ||
C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study | Q45256250 | ||
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy | Q45263389 | ||
Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room | Q46668016 | ||
Acute coronary syndromes without ST-segment elevation--what is the role of early intervention? | Q46703406 | ||
P433 | issue | 9 | |
P921 | main subject | lipoprotein | Q28350 |
acute coronary syndrome | Q266018 | ||
P304 | page(s) | 604-612 | |
P577 | publication date | 2007-06-27 | |
P1433 | published in | Clinical Research in Cardiology | Q2665050 |
P1476 | title | Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). | |
P478 | volume | 96 |
Q37148410 | A cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants |
Q42471464 | Altered nitric oxide/cGMP platelet signaling pathway in platelets from patients with acute coronary syndromes |
Q26853640 | Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome? |
Q44015753 | Coronary surgery for acute coronary syndrome: which determinants of outcome remain? |
Q37994308 | Developing and assessing cardiovascular biomarkers |
Q35059506 | Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study |
Q39912642 | Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease |
Q33536648 | Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature |
Q37445865 | Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target |
Q37729873 | Lipoprotein-associated phospholipase A2: a new therapeutic target. |
Q33764961 | Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke. |
Q33664272 | Lp-PLA2 Inhibition-The Atherosclerosis Panacea? |
Q36145180 | Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 |
Q38138969 | Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management |
Q36913018 | Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in? |
Q35764402 | Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis |
Q37902963 | The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk |
Q83474563 | [Cardiac biomarkers in the critically ill] |
Search more.